Regulation of collateral blood vessel development by the innate and adaptive immune system

Trends in Molecular Medicine

Volumn 18, Issue 8, 2012, Pages 494-501

  La Sala, Andrea ^a   Pontecorvo, Laura ^a   Agresta, Alessia ^b   Rosano, Giuseppe ^c   Stabile, Eugenio ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b Centro Polidiagnostico Stabile   (Italy)

^c San Raffaele Sulmona ^*  (Italy)

Author keywords

Arteriogenesis; Collateral vessel growth; Ischemia; Macrophages; Regulatory t cells; T helper lymphocytes

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ARTERIOLE; ARTERY BLOOD FLOW; CAPILLARY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; COLLATERAL BLOOD VESSEL DEVELOPMENT; GENE EXPRESSION; HUMAN; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ADAPTIVE IMMUNITY; ANIMALS; BLOOD VESSELS; COLLATERAL CIRCULATION; HUMANS; IMMUNITY, INNATE; LYMPHOCYTES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84864382518     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.06.007     Document Type: Review

References (60)

1. Alon R., Ley K. Cells on the run: shear-regulated integrin activation in leukocyte rolling and arrest on endothelial cells. Curr. Opin. Cell Biol. 2008, 20:525-532.
2. Cai W., Schaper W. Mechanisms of arteriogenesis. Acta Biochim. Biophys. Sin. (Shanghai) 2008, 40:681-692.
3. Heil M., Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ. Res. 2004, 95:449-458.
4. Epstein S.E., et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 2004, 109:2826-2831.
5. Nishina P.M., et al. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids 1993, 28:599-605.
6. Scholz D., et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J. Mol. Cell. Cardiol. 2002, 34:775-787.
7. Lee C.W., et al. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. J. Am. Coll. Cardiol. 2004, 43:474-482.
8. Walz A., et al. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J. Exp. Med. 1991, 174:1355-1362.
9. Engelhardt E., et al. Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am. J. Pathol. 1998, 153:1849-1860.
10. Raman D., et al. Chemokines in health and disease. Exp. Cell Res. 2011, 317:575-589.
11. Hiromatsu Y., Toda S. Mast cells and angiogenesis. Microsc. Res. Tech. 2003, 60:64-69.
12. Heissig B., et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J. Exp. Med. 2005, 202:739-750.
13. Hannon R., et al. Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J. 2003, 17:253-255.
14. Meisner J.K., Price R.J. Spatial and temporal coordination of bone marrow-derived cell activity during arteriogenesis: regulation of the endogenous response and therapeutic implications. Microcirculation 2010, 17:583-599.
15. Heil M., et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H2411-H2419.
16. Arras M., et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J. Clin. Invest. 1998, 101:40-50.
17. Pipp F., et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ. Res. 2003, 92:378-385.
18. Bergmann C.E., et al. Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J. Leukoc. Biol. 2006, 80:59-65.
19. Capoccia B.J., et al. Recruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1-dependent fashion. J. Leukoc. Biol. 2008, 84:760-768.
20. Schirmer S.H., et al. Blocking interferon {beta} stimulates vascular smooth muscle cell proliferation and arteriogenesis. J. Biol. Chem. 2010, 285:34677-34685.
21. Khmelewski E., et al. Tissue resident cells play a dominant role in arteriogenesis and concomitant macrophage accumulation. Circ. Res. 2004, 95:E56-E64.
22. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22:231-237.
23. Takeda Y., et al. Macrophage skewing by Phd2 haplodeficiency prevents ischemia by inducing arteriogenesis. Nature 2011, 479:122-126.
24. Shireman P.K. The chemokine system in arteriogenesis and hind limb ischemia. J. Vasc. Surg. 2007, 45(Suppl. A):A48-A56.
25. Ito W.D., et al. Monocyte Chemotactic Protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ. Res. 1997, 80:829-837.
26. Hoefer I.E., et al. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc. Res. 2001, 49:609-617.
27. van Royen N., et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ. Res. 2003, 92:218-225.
28. Voskuil M., et al. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H1422-H1428.
29. Heil M., et al. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-Chemokine Receptor-2. Circ. Res. 2004, 94:671-677.
30. Heil M., et al. Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur. J. Cell Biol. 2000, 79:850-857.
31. Barleon B., et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343.
32. van Royen N., et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J. 2002, 16:432-434.
33. Baffour R., et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J. Vasc. Surg. 1992, 16:181-191.
34. Deindl E., et al. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis. Circ. Res. 2003, 92:561-568.
35. Cao R., et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 2003, 9:604-613.
36. de Groot D., et al. Arteriogenesis requires toll-like receptor 2 and 4 expression in bone-marrow derived cells. J. Mol. Cell. Cardiol. 2011, 50:25-32.
37. Couffinhal T., et al. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. Circulation 1999, 99:3188-3198.
38. Zhu J., et al. Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 2010, 28:445-489.
39. Blotnick S., et al. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:2890-2894.
40. Freeman M.R., et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 1995, 55:4140-4145.
41. Stabile E., et al. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation 2003, 108:205-210.
42. Stabile E., et al. CD8+ T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4+ mononuclear cells through the expression of interleukin-16. Circulation 2006, 113:118-124.
43. Kumamoto Y., et al. CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8749-8754.
44. Cruikshank W., Little F. Interleukin-16: the ins and outs of regulating T cell activation. Crit. Rev. Immunol. 2008, 28:467-483.
45. Schwab J.M., et al. Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages. J. Neuroimmunol. 2001, 114:232-241.
46. Martin-Fontecha A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-[gamma] for TH1 priming. Nat. Immunol. 2004, 5:1260-1265.
47. van Weel V., et al. Natural killer cells and CD4+ T cells modulate collateral artery development. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2310-2318.
48. Chalothorn D., Faber J.E. Strain-dependent variation in collateral circulatory function in mouse hindlimb. Physiol. Genomics 2010, 42:469-479.
49. Chen X., et al. BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J. Leukoc. Biol. 2005, 78:114-121.
50. Shalev I., et al. Making sense of regulatory T cell suppressive function. Semin. Immunol. 2011, 23:282-292.
51. Mallat Z., et al. Regulatory T cell immunity in atherosclerosis. Trends Cardiovasc. Med. 2007, 17:113-118.
52. Sasaki N., et al. Regulatory T cells in atherogenesis. J. Atheroscler. Thromb. 2012, 19:503-515.
53. Zouggari Y., et al. Regulatory T cells modulate postischemic neovascularization. Circulation 2009, 120:1415-1425.
54. Lenschow D.J., et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996, 5:285-293.
55. Cosmi L., et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 2004, 103:3117-3121.
56. Hellingman A.A., et al. A limited role for regulatory T cells in post-ischemic neovascularization. J. Cell. Mol. Med. 2012, 16:328-336.
57. Hata T., et al. Critical role of Th17 cells in inflammation and neovascularization after ischaemia. Cardiovasc. Res. 2011, 90:364-372.
58. Seiler C., et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001, 104:2012-2017.
59. van Royen N., et al. START trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005, 112:1040-1046.
60. Zbinden S., et al. Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease. J. Am. Coll. Cardiol. 2005, 46:1636-1642.